ArticleKorean circulation journal2026
IL-12Rβ2 is Expressed in the Synthetic SMC and Detected in the Blood of Patients With Acute Myocardial Infarction.
Article in Korean circulation journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
objectivesDe-differentiation and proliferation of smooth muscle cells (SMCs), triggered by pro-atherogenic factors or endothelial damage, contribute to progressive vascular remodeling. However, biomarkers reflecting the SMC phenotypic changes indicative of vulnerable plaques remain unavailable.
methodsWe characterized mRNA and protein expression of interleukin-12 receptor beta 2 subunit (IL-12Rβ2) in human aortic SMCs and human carotid arteries with atherosclerotic lesions by quantitative real-time polymerase chain reaction, immunoblotting, flow cytometry, and immunohistochemistry. Functional roles of IL-12Rβ2 were evaluated by siRNA-mediated knockdown in synthetic SMCs and a rat carotid balloon injury model. A capture enzyme-linked immunosorbent assay (ELISA) was developed to measure circulating IL-12Rβ2 levels in plasma from patients with acute coronary syndromes.
resultsThe IL-12Rβ2 protein is about 2-fold higher in the thickened carotid arteries from patients with atherosclerosis than in normal arteries. The in vitro studies demonstrate that IL-12Rβ2 expression is induced in synthetic SMCs by interferon (IFN)-γ stimulation. The knockdown of IL-12Rβ2 significantly reduces proliferation, migration, and monocyte adhesion in synthetic SMCs and inhibits neointimal thickening in a rat carotid balloon injury model. IL-12Rβ2 is detected in SMC-derived extracellular vesicles (EVs) circulating in plasma from acute myocardial infarction (AMI) patients and is successfully quantified using a capture ELISA employing anti-PDGFRβ antibody as an SMC-specific marker.
conclusionsIL-12Rβ2, selectively induced in synthetic SMCs by IFN-γ, is released via EVs into blood in AMI patients, representing a novel biomarker to detect vulnerable atherosclerotic plaques through the newly-developed ELISA system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.